Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate maternal nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B2 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B2 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.
Type:
Application
Filed:
December 26, 2023
Publication date:
April 18, 2024
Inventors:
Cyrus Cooper, Peter David Gluckman, Keith Malcolm Godfrey, Catherine Mace, Irma Silva Zolezzi
Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.
Type:
Application
Filed:
December 22, 2023
Publication date:
April 18, 2024
Inventors:
D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
Abstract: A method of treating a subject with a cancerous tumor exhibiting an inactivating mutation in the PTEN gene including administering to the subject trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenylcyclobutanol or a pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to a compound ABT-263 or a derivative thereof for use in the treatment of uveal melanoma and/or uveal melanoma resistant. Inventors provide evidence that ABT-263 displays clear antiproliferative and proapoptotic activities in metastatic uveal melanoma cells both in vitro and in vivo. They also demonstrated that ABT-263 effect is accompanied with the activation of the ER stress response pathway that exerts cytoprotective effect. Blocking ER stress enhanced ABT-263 killing efficacy. The combination of ABT-263 with PERK inhibition synergistically reduced the survival rate of primary uveal melanoma cells.
Type:
Application
Filed:
October 28, 2020
Publication date:
April 18, 2024
Inventors:
Robert BALLOTTI, Corine BERTOLOTTO-BALLOTTI
Abstract: The disclosure provides methods for rescuing defects caused by abnormal CDKL5 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, a muscarinic receptor inhibitor, a GSK3 inhibitor, a Notch inhibitor and any combination thereof. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, CDKL5-mosaic neurospheres, and cortical organoids).
Abstract: Disclosed herein are compounds and methods for the treatment of disturbances to cerebral homeostasis using isoquinoline derivatives and pharmaceutical compositions thereof.
Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.
Type:
Application
Filed:
December 24, 2021
Publication date:
April 18, 2024
Applicants:
NATIONAL CANCER CENTER, Sumitomo Pharma Co., Ltd.
Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.
Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.
Abstract: Pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, which exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. Manufacturing process and methods of use are also provided. The pharmaceutical compositions are used for prevention, treatment or prophylaxis of disorders in human patients in need thereof. Oral pharmaceutical compositions of mifepristone, methods for their administration, processes for their production, and use of these compositions are described for the treatment of diseases for which mifepristone is indicated.
Type:
Application
Filed:
December 6, 2023
Publication date:
April 18, 2024
Applicant:
SLAYBACK PHARMA LLC
Inventors:
Paras P. JAIN, Somnath Devidas NAVGIRE, Sumitra Ashokkumar PILLAI
Abstract: This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.
Type:
Application
Filed:
January 27, 2022
Publication date:
April 18, 2024
Inventors:
Vijayveer BONTHAPALLY, Ellison SUTHOFF, Handan GUNDUZ-BRUCE, Ryan ARNOLD
Abstract: A method of treating a cholecalciferol (VD) deficiency associated condition in a patient comprising administering a pharmacologically effective does of a pharmaceutical composition containing VD and one of glutathione (GSH) and a GSH precursor. A pharmaceutical composition for treating a cholecalciferol (VD) deficiency associated condition comprising a pharmacologically effective does of VD and one of glutathione (GSH) and a GSH precursor.
Abstract: There is disclosed a composition comprising cannabidiol (CBD) and one or more cannabinoids selected from cannabidiolic acid (CBDA), cannabigerol (CBG) and cannabigerolic acid (CBGA) for use in the treatment or prevention of inflammation and disorders associated with inflammation or an IL-6 related disorder.
Type:
Application
Filed:
February 8, 2022
Publication date:
April 18, 2024
Applicants:
TTS Pharma Ltd, Aberystwyth University
Inventors:
Robert WALTON, Mark TUCKER, Debbie NASH, Nathan ALLEN, Ruth WONFOR, Ifat SHAH
Abstract: Compositions for preventing and reversing ultraviolet (UV) radiation damage, preventing antimicrobial drug resistance, protecting a subject from acute radiation syndrome, reducing hair loss resulting from alopecia areata, reducing a probability of cervical cancer, reducing hair loss resulting from radiation therapy or chemotherapy, preventing complications arising from cosmic radiation exposure, preventing complications arising from a disease causing excess mucus formation, reducing a likelihood of infertility in cancer patients, preventing genomic instability from a diagnostic imaging or interventional radiology procedure, preventing radiation therapy-induced organ damage, preventing chemotherapy-associated peripheral neuropathy, protecting skin cells from radiation dermatitis, preventing radiation-induced fibrosis, and reducing ventilator-induced lung injury are provided. The composition includes a target compound.
Type:
Application
Filed:
November 22, 2021
Publication date:
April 18, 2024
Inventors:
David GRDINA, Jonathan PESKOFF, Jonathan ROSEN
Abstract: A method of treating or preventing various bone-related diseases and disorders in a human using an effective amount of citicoline with or without other nutraceutical agents is disclosed. The citicoline (Cytidine Diphosphate choline or Cytidine 5?-diphosphocholine) is administrated to the patient or human in need of such treatment to prevent osteoporosis, promote healing in delayed union, non-union, infected non-union of fracture, acceleration of osteoporotic fracture healing and spinal cord regeneration in spinal cord injury in combination with bone marrow aspirate. The effective amount of citicoline is administered topically, orally or injected into the human body to promote tissue repair. Further, the method of treating patients using an effective amount of citicoline with or without other nutraceutical agents accelerates fracture healing.
Type:
Application
Filed:
December 12, 2022
Publication date:
April 18, 2024
Inventors:
P S. John, Varghese Thomas, Ann Maria John
Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
Type:
Application
Filed:
December 20, 2023
Publication date:
April 18, 2024
Inventors:
Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol, High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.
Type:
Application
Filed:
September 11, 2023
Publication date:
April 18, 2024
Inventors:
Thomas E Barta, Jonathan W. Bourne, Kyle D. Monroe, Michael M. Muehlemann
Abstract: Provided herein are compositions, such as topical formulations, that contain one or more fractions, portions, or components of human milk and methods of using and manufacturing the same. In some aspects, the provided compositions include human milk cream or one or more fatty acids found in or native to human milk. Also included are methods for treating or preventing skin conditions, such as atopic dermatitis or psoriasis.
Type:
Application
Filed:
January 21, 2022
Publication date:
April 18, 2024
Inventors:
Biranchi PATRA, Adam SUN, Victoria NIKLAS
Abstract: The present disclosure relates to methods of modulating level of pathogenic E. coli (EHEC, EPEC, APEC) present in the gastrointestinal tract of an animal by administering saccharide compositions comprising an anhydro moiety. The presence/load with pathogenic E. coli strains can be assessed via the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal.
Type:
Application
Filed:
February 15, 2022
Publication date:
April 18, 2024
Inventors:
Ghislain SCHYNS, Joshua CLAYPOOL, Kevin FREEMAN
Abstract: The present invention relates to a pharmaceutical composition for the treatment of neuroinflammation including eleutheroside B as an active ingredient, and more particularly, to a pharmaceutical composition for treating neuroinflammatory disease in patients with the increased activity of astrocytes or microglia, comprising eleutheroside B or a pharmaceutically acceptable salt thereof as an active ingredient.
Type:
Application
Filed:
October 18, 2021
Publication date:
April 18, 2024
Applicant:
YEP BIO CO. LTD.
Inventors:
Chi Hu PARK, Hyoung Shik KIM, Yoori CHOI
Abstract: Provided herein are pharmaceutical compositions comprising therapeutic agent(s) and functional excipients that can enable oral absorption of small molecules and/or large molecules. Also provided herein are methods of preparing the pharmaceutical composition and methods of using the same for treating various diseases or disorders such as type-2 diabetes, obesity, NASH, renal disease.
Type:
Application
Filed:
December 20, 2022
Publication date:
April 18, 2024
Inventors:
Steven DINH, Huadong TANG, Wenfei LIANG
Abstract: The present disclosure relates to the field of medicine and specifically to an application of naringin combined with rapamycin in preparation of medications for treating hyperlipidemia. Naringin achieves anti-inflammatory and lipid-lowering effects by inhibiting the formation of oxLp-NLRP3 complexes. The present disclosure has been substantiated through cellular experiments and animal experiments, it demonstrates that naringin effectively intervenes in the early progression of hyperlipidemia by neutralizing oxLp and inhibiting the formation of oxLp-NLRP3 complexes. The inhibitory effect of naringin on oxLp-NLRP3 complexes contributes to unleashing the therapeutic potential of rapamycin in hyperlipidemia, providing a combined strategy for the prevention and treatment of hyperlipidemia-related diseases in clinical applications.
Abstract: The invention concerns nicotinamide mononucleotide, a pharmaceutically acceptable derivative, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of rheumatoid arthritis, as well as compositions comprising it.
Abstract: Disclosed herein are compositions for supporting bladder health and/or treating, ameliorating, preventing, or reducing overactive bladder or the symptoms associated therewith. The compositions disclosed herein comprise a beta-adrenergic receptor agonist and at least one muscarinic receptor antagonist. Also described herein are methods utilizing the aforementioned compositions.
Type:
Application
Filed:
October 18, 2023
Publication date:
April 18, 2024
Inventors:
James R. Komorowski, Sarah Sylla, Devon Bernsley
Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.
Type:
Application
Filed:
December 18, 2023
Publication date:
April 18, 2024
Inventors:
Avak KAHVEJIAN, Alexandra Sophie De Boer, Nicholas McCartney Plugis, Erica Gabrielle Weinstein, Sebastian Trousil, Morag Helen Stewart, Ki Young Paek, Catherine Cifuentes-Rojas
Abstract: A composition including Lumasiran and/or Nedosiran for use in the treatment or prevention of an oxalate-related disorder in a patient receiving dialysis treatment who does not suffer from Primary Hyperoxaluria 1-3 (PH), preferably a cardiovascular disease. In further aspects of the invention, the composition includes Lumasiran and Nedosiran diminishes or blocks hepatic oxalate production in non-PH dialysis receiving patients to prevent or treat cardiovascular events, sudden cardiac death, congestive heart failure, and excess mortality in said patients. Also disclosed are methods of administration, a method for preparing the composition including Lumasiran and/or Nedosiran and a kit including Lumasiran and/or Nedosiran and instructions for its use.
Abstract: The invention relates to a prebiotic composition for use in a method of therapeutic or prophylactic treatment of disorders associated with disturbed composition or functionality of the intestinal microbiome in a subject, said use comprising oral administration of the prebiotic composition to the subject, wherein the composition contains at least 0.1% by weight of dry matter of RG-I polysaccharides originating from fruit, carrot, pea, chicory or sugar beet, said RG-I polysaccharides having a molecular weight in excess of 15 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 20:1 to 1:1.
Abstract: The present invention provides a pharmaceutical composition for use in the prevention or treatment of a condition associated with a reduction in the number of Lactobacilli in the vagina of a subject relative to a healthy subject, wherein the composition comprises from 1.3 to 1.7 w/v % glycogen and less than 0.1 w/v % lactic acid.
Type:
Application
Filed:
November 27, 2021
Publication date:
April 18, 2024
Inventors:
Paul Long, Alastair Sutcliffe, Catherine Tuleu
Abstract: The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.
Abstract: The invention provides methods and compositions for blocking access to, and reducing infiltration into, the brain of a subject through the subject's olfactory nerves, olfactory support structures, or both, of one or more pathogenic or anthropogenic environmental factor by contacting the surface of the olfactory epithelium with a polyanionic polysaccharide-chitosan composition.
Abstract: A pH-responsive hydrogel, which is synthesized by using mixed pectin and sucralfate treated with a small amount of acid to form a pH-responsive hydrogel. The pH-responsive hydrogel can form a temporary coating on the surface of the gastrointestinal tract to reduce excessive nutrient absorption, and exhibits excellent barrier properties and mucosal adhesion effects, which are useful for reducing blood sugar rise and weight gain, the liver fat accumulation, body fat accumulation and blood low-density lipoprotein that have a significant effect. In addition, the technical principles disclosed in the pH-responsive hydrogel should be applied to other polymer materials to manufacture different pH-responsive hydrogels.
Abstract: The disclosure is directed to methods of reducing blood pressure, treating hypertension, improving athletic performance, and increasing aerobic capacity, stamina, muscle strength, endurance, and/or time to exhaustion in a subject comprising co-administering to the subject elemental metal and a source of nitrate anion (NO3?). The disclosure is also directed to related compositions comprising elemental metal and a source of nitrate anion (NO3?).
Abstract: The disclosure is directed to methods of reducing blood pressure, treating hypertension, improving athletic performance, and increasing aerobic capacity, stamina, muscle strength, endurance, and/or time to exhaustion in a subject comprising co-administering to the subject elemental metal and a source of nitrate anion (NO3?). The disclosure is also directed to related compositions comprising elemental metal and a source of nitrate anion (NO3?).
Abstract: The disclosure is directed to methods of reducing blood pressure, treating hypertension, improving athletic performance, and increasing aerobic capacity, stamina, muscle strength, endurance, and/or time to exhaustion in a subject comprising co-administering to the subject elemental metal and a source of nitrate anion (NO3?). The disclosure is also directed to related compositions comprising elemental metal and a source of nitrate anion (NO3?).
Abstract: The disclosure is directed to methods of reducing blood pressure, treating hypertension, improving athletic performance, and increasing aerobic capacity, stamina, muscle strength, endurance, and/or time to exhaustion in a subject comprising co-administering to the subject elemental metal and a source of nitrate anion (NO3?). The disclosure is also directed to related compositions comprising elemental metal and a source of nitrate anion (NO3?).
Abstract: The present invention provides new storable and stable disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The component in the device is devoid of stability issues, since the solid precursors are instantly to be dissolved in water or a pharmaceutically acceptable diluent, adjuvant, or carrier, and combined with an activator, e.g. adipic or succinic acid or their salts, optionally combined with a viscosity enhancer, optionally combined with a dye. The main product according to the invention is generated by dissolving effervescent material in the form of tablets or granules, the resulting solutions from dissolution of the effervescent material are useful disinfectants for treating a broad spectrum of pathogenic bacterial and/or viral, fungal, or parasitic pathogens, denoted microbials.
Abstract: Provided herein are anti-pathogen compositions that are suspensions or solutions (e.g., a homogeneous solution) in water (e.g., tap water or distilled water), saline, and/or a solvent comprising about 0.000000001% to about 5% by weight of an active component, wherein the active component is or comprises particles (e.g., ionic particles, microparticles, or nanoparticles) of an activated metal. The present disclosure further provides various uses for anti-pathogenic liquid compositions described herein.
Abstract: Ligand-bound zinc sulfide nanoparticles, the method of preparing the ligand-bound zinc sulfide nanoparticles, composition containing ligand-bound zinc sulfide nanoparticles, uses of the ligand-bound zinc sulfide nanoparticles and composition containing the ligand-bound zinc sulfide nanoparticles, including inhibiting the fibrosis of amyloid-? (A?) and reducing the expression of inflammatory factors, treatment of A? fibrosis-caused/related Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal ganglion cell degeneration in glaucoma (RGCD) or myositis/myopathy (MM), and to prepare drugs for the treatment of AD, CAA, RGCD or MM, and methods for treating the above diseases.
Type:
Application
Filed:
March 23, 2021
Publication date:
April 18, 2024
Applicant:
Wuhan Vast Conduct Science Foundation CO., LTD.
Abstract: The present invention provides methods of treating myopia comprising administering composition comprising a cop-per-containing agent to an eye of a subject in need thereof.
Abstract: The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon ? and an inflammation-activating lipid which can produced hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment.
Abstract: The present invention provides an immune effector cell that comprises a chimeric antigen receptor (CAR) specific for a tag of a tagged polypeptide, wherein said polypeptide binds to an antigen of a target cell, and a chimeric costimulatory receptor (CCR) specific for a further antigen. The CCR is not able to mediate said immune response on its own but boosts the immune response of said immune effector cell triggered by the CAR.
Type:
Application
Filed:
December 19, 2023
Publication date:
April 18, 2024
Inventors:
Dominik Lock, Mario Assenmacher, Andrew Kaiser
Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional-group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.
Abstract: The present disclosure relates to retroviral vectors comprising polynucleotides encoding hapten-binding receptors and T cell activating receptors. The retroviral vectors may also comprise transduction enhancers. Also disclosed are adaptor molecules and their use in conjunction with the retroviral vectors and T cells transduced with the retroviral vectors.
Abstract: Described herein are chimeric receptors comprising G-CSFR extracellular domains and the intracellular domains of various multi-subunit cytokine receptors for selective activation of cytokine signaling in cells of interest. In certain aspects, the selective activation of cytokine signaling in cells expressing the chimeric receptors described herein includes the ability to specifically stimulate adoptively transferred cells.
Type:
Application
Filed:
October 8, 2020
Publication date:
April 18, 2024
Inventors:
Brad Nelson, Megan Fuller, Martin J. Boulanger
Abstract: Disclosed herein are chimeric antigen receptors (CARs) that include (a) an extracellular scFv comprising a light chain variable domain (VL) a heavy chain variable domain (VH), wherein the scFv specifically binds to an antigen of interest; (b) a CD8 hinge domain and transmembrane domain; and (c) a cytoplasmic domain comprising (i) a TIM-3 cytoplasmic domain and an intracellular signaling domain, wherein (a)-(c) are in N-terminal to C-terminal order. Also disclosed are nucleic acid molecules encoding these CARs, host cells transformed with these nucleic acids, and the use of these compositions for treating a subject, such as a subject with a tumor.
Type:
Application
Filed:
October 16, 2020
Publication date:
April 18, 2024
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Lawrence Patrick Kane, Jason Lohmueller
Abstract: The present disclosure provides anti-CCR4 chimeric antigen receptors (CARs) and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising anti-CCR4 CARs. Also provided are methods of using the anti-CCR4 CAR-expressing cells to treat cancer and T cell-depleting systems for use in combination with anti-CCR4 CAR T cell therapy.
Type:
Application
Filed:
February 10, 2022
Publication date:
April 18, 2024
Inventors:
Carl H. June, Keisuke Watanabe, Regina M. Young, John Scholler, Hiroyoshi Nishikawa
Abstract: A chimeric antigen receptor fusion protein co-expressing IL-7 and CCR2b, and application thereof are provided. The fusion protein includes a chimeric antigen receptor, a 2A peptide, IL-7, a 2A peptide and CCR2b which are sequentially linked in series.
Type:
Application
Filed:
March 30, 2021
Publication date:
April 18, 2024
Inventors:
Guangchao LI, Min LUO, Wen DING, Xuejun WANG
Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
Type:
Application
Filed:
December 26, 2023
Publication date:
April 18, 2024
Inventors:
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.